| Applied DNA Reports Second Quarter Fiscal 2025 Financial Results |
- Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET - STONY BROOK, NY / ACCESS Newswire / May 15, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its second quarter of fiscal 2025 ended March 31, 2025. The Company's Form 10-Q for its fiscal second quarter can be viewed on the SEC Filings page of its Investor Relations website. |
accessnewswire.com |
2025-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 |
Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines |
globenewswire.com |
2025-05-15 12:05:00 |
Czytaj oryginał (ang.) |
| Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3 |
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website. |
accessnewswire.com |
2025-05-14 15:30:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience and Ginkgo Bioworks Revise Collaboration |
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Under the terms of the revised three-year $15 million agr. |
businesswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript |
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Mark Massaro - BTIG Tejas Savant - Morgan Stanley Evie Koslosky - Goldman Sachs Matt Larew - William Blair Brendan Smith - TD Cowen Operator [Call Starts Abruptly] live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. |
seekingalpha.com |
2025-05-07 01:19:04 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates |
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago. |
zacks.com |
2025-05-06 23:30:39 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Reports First Quarter 2025 Financial Results |
Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. |
prnewswire.com |
2025-05-06 21:00:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience Spins Out DNA Data Storage as Independent Company |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that the company has spun out its DNA data storage technology application as an independent company, named Atlas Data Storage (“Atlas”). “There are many applications of synthetic DNA with the potential to have an incredible impact on the world. With this spin out, both Twist and Atlas are. |
businesswire.com |
2025-05-05 11:10:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade |
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $7.37, representing a -0.14% change from its previous close. |
zacks.com |
2025-04-30 23:20:46 |
Czytaj oryginał (ang.) |
| Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors |
Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors. |
prnewswire.com |
2025-04-30 13:00:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation |
Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON , April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available. |
prnewswire.com |
2025-04-29 20:00:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Holdings, Inc. (DNA) Rises Yet Lags Behind Market: Some Facts Worth Knowing |
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60, marking a +0.8% move from the previous day. |
zacks.com |
2025-04-23 23:21:27 |
Czytaj oryginał (ang.) |
| Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation |
BOSTON , April 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market. This advanced modular laboratory automation platform will be deployed at Aura Genetics' new 22,000-square-foot high-throughput facility at the UPS Healthcare Labport, located at the end of the runway at the Louisville, KY airport. |
prnewswire.com |
2025-04-22 13:00:00 |
Czytaj oryginał (ang.) |
| Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA |
- Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA™ and LineaIVT™ platforms from U.S.-based suppliers. The initiative, undertaken in response to the 2024 BIOSECURE Act and customer demand for a U.S.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the U.S. in response to potential tariff impacts and to ensure a stable supply chain. |
accessnewswire.com |
2025-04-21 13:00:00 |
Czytaj oryginał (ang.) |
| Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors |
STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025. |
prnewswire.com |
2025-04-17 11:30:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain |
Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , April 10, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences , US Pharmacopeia (USP), On Demand Pharmaceuticals , and Isolere Bio by Donaldson . This two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems. |
prnewswire.com |
2025-04-10 13:00:00 |
Czytaj oryginał (ang.) |
| 23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors |
Sen. Bill Cassidy is probing 23andMe, which recently filed for bankruptcy protection, to ensure the company does not sell customer data to China or other foreign adversaries. |
foxbusiness.com |
2025-04-09 14:16:41 |
Czytaj oryginał (ang.) |
| Focus Graphite Advanced Materials Commences Work Program with AETC for C4V Digital DNA(TM) Testing and Strategic Specialty Applications |
Exclusion of Canadian natural graphite from President Trump's "Liberation Day" U.S. Tariffs underscores urgency to fast-track testing and qualification with industry partners. OTTAWA, ON / ACCESS Newswire / April 9, 2025 / Focus Graphite Advanced Materials Inc. (TSXV:FMS)(OTCQB:FCSMF)(FSE:FKC) ("Focus" or the "Company"), is pleased to announce the commencement of its advanced material preparation and testing program in collaboration with U.S.-based Advanced Energy Technologies Corp. ("AETC"), a leading processor of industrial graphite and carbon materials for the upstream and advanced downstream applications. |
accessnewswire.com |
2025-04-09 09:00:00 |
Czytaj oryginał (ang.) |
| Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement |
STONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). As previously reported, the Company was notified on November 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. |
accessnewswire.com |
2025-04-08 13:00:00 |
Czytaj oryginał (ang.) |
| What's next for 23andMe and all that DNA data? |
As 23AndMe files for bankruptcy, customers are left wondering what happens to their DNA data? On this episode of the Big Take podcast, we discuss what this means for millions of users' genetic data and for the future of the genetic testing industry. |
youtube.com |
2025-04-06 22:24:54 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks: Revenue Struggles Continue |
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks. |
seekingalpha.com |
2025-02-27 12:29:49 |
Czytaj oryginał (ang.) |
| 2025 Is Make Or Break For Ginkgo Bioworks |
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway. |
seekingalpha.com |
2025-02-27 08:19:27 |
Czytaj oryginał (ang.) |
| Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday. |
benzinga.com |
2025-02-26 10:10:23 |
Czytaj oryginał (ang.) |
| IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19 |
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology |
globenewswire.com |
2025-02-26 10:05:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript |
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith - TD Cowen Matt Larew - William Blair & Company Joseph Fridman Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year. |
seekingalpha.com |
2025-02-25 23:22:28 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates |
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $3.60 per share a year ago. |
zacks.com |
2025-02-25 21:31:10 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results |
Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON , Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial information will be available at investors.ginkgobioworks.com. |
prnewswire.com |
2025-02-25 19:00:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio |
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio's DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and n. |
businesswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab |
BOSTON , Feb. 21, 2025 /PRNewswire/ -- Volta Labs , a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow. "I like the Apps and the App Store concept on Callisto. |
prnewswire.com |
2025-02-21 11:00:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care |
International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness BOSTON , Feb. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and Digital Executive Agency (HaDEA) as contracting authority under a joint tender of up to €24 million. The funding is made available through the EU4Health programme, linked to the key priorities of the Health Emergency Preparedness and Response Authority (HERA) of the European Commission. |
prnewswire.com |
2025-02-20 10:01:00 |
Czytaj oryginał (ang.) |
| JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors |
STATEN ISLAND, N.Y. , Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Japanese Patent Office (JPO) in January 2025. |
prnewswire.com |
2025-02-19 10:00:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation |
Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON , Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2024, on Tuesday, February 25, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available. |
prnewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| DNA from Fiserv Selected by Third Federal as Part of its Digital Transformation |
MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced it will deliver digital innovation through the award-winning DNA® platform to Third Federal Savings & Loan. The platform will better equip Third Federal to serve account holders through future-ready technologies and real-time transactions via all channels, propelling customization and growth. Third Federal, a $17bn bank based in Cleveland, selected DN. |
businesswire.com |
2025-02-14 11:42:00 |
Czytaj oryginał (ang.) |
| Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress |
- Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified for Commercial Operation in January - - Webcast and Conference Call Scheduled for today at 4:30 PM ET - STONY BROOK, NY / ACCESS Newswire / February 13, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its first quarter of fiscal 2025 ended December 31, 2024. The Company's Form 10-Q, once filed, can be viewed on the SEC Filings page of its Investor Relations website. |
accessnewswire.com |
2025-02-13 18:03:00 |
Czytaj oryginał (ang.) |
| Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025 |
Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025. The Company will host a conference call for shareholders and the investment community at 4:30 p.m. |
accessnewswire.com |
2025-02-12 14:00:00 |
Czytaj oryginał (ang.) |
| Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14 |
STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the "Special Meeting") to be held on Friday, February 14, 2025 at 11:00 a.m. The Company's Board of Directors encourages any shareholder as of the record date of November 25, 2024, who has not yet voted their shares on the Warrant Exercise Proposal (as defined below), to contact Kingsdale Advisors to vote their shares: 1-855-682-9644 or by e-mail at contactus@kingsdaleadvisors.com. |
accessnewswire.com |
2025-02-11 10:30:00 |
Czytaj oryginał (ang.) |
| Mercado Libre CEO and Founder Marcos Galperin Reflects on the company's 25-Year Journey and DNA in Latest Episode of Inside Mercado Libre |
Montevideo, Uruguay, 6 February 2025, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mercado Libre (NASDAQ: MELI), the leading e-commerce and fintech platform in Latin America, drops the fifth episode of its podcast series, Inside Mercado Libre, "Marcos Galperin on MELI's Culture” featuring its CEO and founder Marcos Galperin. The Inside Mercado Libre podcast, hosted by Investor Relations Officer, Richard Cathcart, provides investors with unique access to the company executives' strategic views. |
globenewswire.com |
2025-02-06 11:55:00 |
Czytaj oryginał (ang.) |
| Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength? |
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-02-06 11:25:24 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series |
Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters. |
prnewswire.com |
2025-02-06 10:01:00 |
Czytaj oryginał (ang.) |
| Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics |
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio. |
globenewswire.com |
2025-02-05 10:00:00 |
Czytaj oryginał (ang.) |
| Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA |
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies - STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synthetic DNA, Linea™ DNA, as a critical component in its manufacture. |
accesswire.com |
2024-12-18 11:00:00 |
Czytaj oryginał (ang.) |
| Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines |
- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / December 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. An update on the buildout of the Company's GMP manufacturing facility is available for viewing via slideshow on the Presentations page of the Investor Relations portion of the Company's website. |
accesswire.com |
2024-12-17 18:05:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy |
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-17 15:01:23 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program |
Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders BOSTON , Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health's (ARPA-H) Resilient Extended Automatic Cell Therapies (REACT) program. |
prnewswire.com |
2024-12-17 10:11:00 |
Czytaj oryginał (ang.) |
| Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out |
STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024. The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. |
accesswire.com |
2024-12-16 12:00:00 |
Czytaj oryginał (ang.) |
| Ferrari has Formula One in its DNA, CEO says after Cadillac supply deal |
Ferrari Chief Executive Benedetto Vigna said Formula One was in the DNA of the company as earlier on Tuesday it announced it would supply engines and gearboxes to a new Cadillac Formula One team in a multi-year agreement from 2026. |
reuters.com |
2024-12-10 17:03:42 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better |
Ginkgo Bioworks reported solid Q3 results, but underlying performance was weaker than the financials suggest after accounting for meaningless non-cash revenue. Ginkgo's new business model focuses on upfront value creation and solutions which reduce friction in the customer acquisition process. While Ginkgo continues to introduce new tools and is landing customers with these products, it is too early to say whether Ginkgo will succeed as a CRO. |
seekingalpha.com |
2024-11-18 12:36:16 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks: Not Enough Progress |
Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have continued to move lower. |
seekingalpha.com |
2024-11-13 10:36:53 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript |
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2024 Results Conference Call November 12, 2024 5:30 PM ET Company Participants Megan LeDuc - Manager, IR Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Conference Call Participants Tejas Savant - Morgan Stanley Matt Sykes - Goldman Sachs John Kim - Bank of America Mark Massaro - BTIG Jacquie Kesa - TD Cowen Megan LeDuc Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. |
seekingalpha.com |
2024-11-13 00:02:05 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates |
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago. |
zacks.com |
2024-11-12 22:00:59 |
Czytaj oryginał (ang.) |
| What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company |
DNA-testing company 23andMe (Nasdaq: ME), once an industry leader that attracted millions of customers, including rapper Snoop Dogg and investor Warren Buffett, has announced significant cuts to its operations, with plans to lay off 200 employees, or roughly 40% of its workforce. The company also said it will discontinue development of its therapeutic programs. |
fastcompany.com |
2024-11-12 19:01:29 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Reports Third Quarter 2024 Financial Results |
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com. |
prnewswire.com |
2024-11-12 19:01:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing |
BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck , known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone payment of $9 million in cash. |
prnewswire.com |
2024-11-12 10:01:00 |
Czytaj oryginał (ang.) |
| Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DN. |
businesswire.com |
2024-11-11 10:30:00 |
Czytaj oryginał (ang.) |
| Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation |
Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON , Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available. |
prnewswire.com |
2024-11-05 09:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market |
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day. |
zacks.com |
2024-11-04 21:20:19 |
Czytaj oryginał (ang.) |
| Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement |
STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Company expected to be approximately $6.5 million before deducting placement agent fees and other estimated expenses payable by the Company. The offering is comprised of 20,312,500 shares (the "Shares") of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.32 per share of common stock (or pre-funded warrants in lieu thereof, which shall have the same purchase price, less the exercise price of $0.0001) in a registered direct offering priced at-the-market under Nasdaq rules. |
accesswire.com |
2024-10-30 09:15:00 |
Czytaj oryginał (ang.) |
| PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 |
New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics |
globenewswire.com |
2024-10-29 11:05:00 |
Czytaj oryginał (ang.) |
| DNA & RNA Banking Services Market Report 2024-2030, Featuring EasyDNA, DNA Genotek, 23andMe, GoodCell, ProteoGenex, Infinity Biologix, deCODE genetics, LGC Biosearch Technologies & PreventionGenetics |
Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application, End-use 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030. |
globenewswire.com |
2024-10-28 07:14:00 |
Czytaj oryginał (ang.) |
| Modifi Biosciences Acquired by Merck |
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers |
globenewswire.com |
2024-10-23 11:05:00 |
Czytaj oryginał (ang.) |